Results 191 to 200 of about 63,989 (248)

Prophylactic-Dose Rivaroxaban Transfer Into Human Milk. [PDF]

Obstet Gynecol
Bruno AM, Job KM, Rower JE, Allshouse AA, Zinkhan EK, Lim MY, Shakib JH, Federspiel JJ, Watt KM, Metz TD, Branch DW.   +10 more
europepmc   +1 more source

Reduced Versus Full-Dose Direct Oral Anticoagulants for Long-Term Management of Venous Thromboembolism: A Systematic Review. [PDF]

J Clin Med
Al Arifi M, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

Rivaroxaban Initiation Timing and Clinical Outcomes After Acute Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation: An IPTW-Based Cohort Study. [PDF]

Clin Appl Thromb Hemost
Hu J, Xia P, Zhang J, Yan X, Ge W, Jiang C.   +5 more
europepmc   +1 more source

Assessment of Pharmacokinetics and Food Effect of AD-109, a Novel Formulation of Rivaroxaban 18 mg. [PDF]

Clin Transl Sci
Ryu H, Cho JY, Lee T, Kim J, Lee S.
europepmc   +1 more source

Uncharted Waters: The OCEAN Trial and the Expanding Indications for AF Ablation. [PDF]

Eur Cardiol
Gill JS, Sagar V, Gallagher MM.
europepmc   +1 more source

Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all? [PDF]

Hemasphere
Lauw MN, Middeldorp S, Carrier M.
europepmc   +1 more source

Exploratory assessment of bleeding risk associated with concurrent use of Anti-VEGF agents and anticoagulants in oncology. [PDF]

Front Pharmacol
Liao D, Zhao Y, Jin Y, Long M, Wang S, Chen S.   +5 more
europepmc   +1 more source

Associations between rivaroxaban dose, gut microbiota, and coagulation parameters in a rat model. [PDF]

Thromb J
Liu Y, Zhang Y, Yang Y, Han C, Zhang Y, Zhou J.   +5 more
europepmc   +1 more source

Tightening Our Belts in the New Healthcare Economy [PDF]

, 2013
Pizzi, Laura, PharmD,MPH
core   +1 more source